Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

It’s a rinse. It’s mouth wash. It’s considered a topical application which has a lower bar provided there is evidence of very low or no systemic exposure. IPIX has already provided sufficient evidence that there is almost no Brilacidin absorption through both the OM and UP results.

Then there is the unmet critical need for both a treatment and a prevention for Oral Mucositis. There are ready pathways for directly to phase 3 under unmet need.

That’s what the end of phase meeting means. The FDA has agreed to meet with IPIX to discuss moving on to phase 3.